Drupal.behaviors.print = function(context) {window.print();window.close();}>

BioMerieux Invests $15M in Quanterix, Will Use SiMoA to Support PSA and Infectious Disease Assays

November 27, 2012

BioMerieux Invests $15M in Quanterix, Will Use SiMoA to Support PSA and Infectious Disease Assays

By Molika Ashford

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Molika Ashford is a GenomeWeb contributing editor and covers personalized medicine and molecular diagnostics. E-mail Molika Ashford.

Related Stories

BioMerieux Takes $15M Stake in Quanterix, Gains Exclusive Global License to SiMoA as IVD Platform

November 30, 2012 / ProteoMonitor
In-Q-Tel Backs Quanterix to Expand Pathogen Detection for Defense Applications

January 10, 2012 / BioArray News
Quanterix Building Commercial Team Ahead of Planned 2013 Launch for Simoa Platform

July 24, 2012 / BioArray News
Following Management Changes, Nanosphere Reports Revenue Growth, but Shortfalls in Dx Placements

February 26, 2013 / BioArray News
BioMerieux Invests $15M in Quanterix as Part of Test Development Partnership

November 15, 2012 / GenomeWeb Daily News